Clinical trials: HER-2 Positive Malignant Carcinoma of Breast
Breast Cancer
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
This study is a Phase 1 and pharmacologic open-label dose-escalation trial using a "3+3" design. Successive cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified.
- Trial name
- NCT01304797
- Testing
- MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Merrimack Pharmaceuticals